Theratechnologies Q1 2022 Earnings Conference Call On April 13, 2022 At 08:30 AM ET
Theratechnologies (NASDAQ:THTX) will host a conference call at 08:30 AM ET on April 13, 2022, to discuss Q1 2022 earnings results.
Theratechnologies To Present 3 Posters At AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition Of Human Cancer Stem-Like Cells (CD133+) In Both Triple-Negative Breast And Ovarian Cancers
Theratechnologies Inc. ("Theratechnologies" or "the Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today
Theratechnologies Submits Supplemental Biologics License Application To FDA Advancing Development Of IV Push Trogarzo For Patients Living With HIV
Theratechnologies Inc. (Theratechnologies or Company) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of
Theratechnologies Announces Renewal Of Shelf Prospectus And Registration Statement; At-The-Market Facility To Be Extended
Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today
Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline
Theratechnologies Inc (NASDAQ:THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The…
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Theratechnologies Q3 EPS $(0.10) Misses $(0.07) Estimate
Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 11.11 percent decrease over losses of $(0.09) per share
Earnings Scheduled For October 13, 2021
Companies Reporting Before The Bell
• BlackRock (NYSE:BLK) is estimated to report quarterly earnings at $9.23 per share on revenue of $4.81 billion.
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.